Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 2c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• Oracle reports earnings today: AI spending bet faces its toughest test yet
• 1-800-FLOWERS.Com (FLWS) Misses Q4 EPS by 10c, Misses on Revenue; Offers Guidance